7yqx › Citations

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75.

Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X
Cell Host Microbe (2022)
Related entries: 7yqt, 7yqu, 7yqv, 7yqw, 7yqy, 7yqz, 7yr0, 7yr1, 7yr2, 7yr3

Cited: 63 times
EuropePMC logo PMID: 36270286

Abstract

Recently emerged SARS-CoV-2 Omicron subvariant, BA.2.75, displayed a growth advantage over circulating BA.2.38, BA.2.76, and BA.5 in India. However, the underlying mechanisms for enhanced infectivity, especially compared with BA.5, remain unclear. Here, we show that BA.2.75 exhibits substantially higher affinity for host receptor angiotensin-converting enzyme 2 (ACE2) than BA.5 and other variants. Structural analyses of BA.2.75 spike shows its decreased thermostability and increased frequency of the receptor binding domain (RBD) in the "up" conformation under acidic conditions, suggesting enhanced low-pH-endosomal cell entry. Relative to BA.4/BA.5, BA.2.75 exhibits reduced evasion of humoral immunity from BA.1/BA.2 breakthrough-infection convalescent plasma but greater evasion of Delta breakthrough-infection convalescent plasma. BA.5 breakthrough-infection plasma also exhibits weaker neutralization against BA.2.75 than BA.5, mainly due to BA.2.75's distinct neutralizing antibody (NAb) escape pattern. Antibody therapeutics Evusheld and Bebtelovimab remain effective against BA.2.75. These results suggest BA.2.75 may prevail after BA.4/BA.5, and its increased receptor-binding capability could support further immune-evasive mutations.

Reviews - 7yqx mentioned but not cited (1)

  1. Distinct Conformations of SARS-CoV-2 Omicron Spike Protein and Its Interaction with ACE2 and Antibody. Lee M, Major M, Hong H. Int J Mol Sci 24 3774 (2023)

Articles - 7yqx mentioned but not cited (1)

  1. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cao Y, Song W, Wang L, Liu P, Yue C, Jian F, Yu Y, Yisimayi A, Wang P, Wang Y, Zhu Q, Deng J, Fu W, Yu L, Zhang N, Wang J, Xiao T, An R, Wang J, Liu L, Yang S, Niu X, Gu Q, Shao F, Hao X, Meng B, Gupta RK, Jin R, Wang Y, Xie XS, Wang X. Cell Host Microbe 30 1527-1539.e5 (2022)


Reviews citing this publication (9)

  1. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Nat Rev Immunol 23 189-199 (2023)
  2. Characterization of SARS-CoV-2 recombinants and emerging Omicron sublineages. Wang Y, Long Y, Wang F, Li C, Liu W. Int J Med Sci 20 151-162 (2023)
  3. The humoral and cellular immune evasion of SARS-CoV-2 Omicron and sub-lineages. Xiang T, Wang J, Zheng X. Virol Sin 37 786-795 (2022)
  4. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. Zhao F, Zai X, Zhang Z, Xu J, Chen W. NPJ Vaccines 7 167 (2022)
  5. Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. Pitsillou E, Yu Y, Beh RC, Liang JJ, Hung A, Karagiannis TC. Clin Exp Med 23 3277-3298 (2023)
  6. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron. Wang L, Møhlenberg M, Wang P, Zhou H. Cytokine Growth Factor Rev 70 13-25 (2023)
  7. Respiratory viruses interacting with cells: the importance of electrostatics. Lauster D, Osterrieder K, Haag R, Ballauff M, Herrmann A. Front Microbiol 14 1169547 (2023)
  8. Staying Ahead of the Game: How SARS-CoV-2 has Accelerated the Application of Machine Learning in Pandemic Management. Williams AH, Zhan CG. BioDrugs 37 649-674 (2023)
  9. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2. Fang L, Xu J, Zhao Y, Fan J, Shen J, Liu W, Cao G. Front Microbiol 14 1228128 (2023)

Articles citing this publication (52)

  1. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, Wang Y, Wang P, Zhao L, Sun H, Yu L, Yang S, Niu X, Xiao T, Gu Q, Shao F, Hao X, Xu Y, Jin R, Shen Z, Wang Y, Xie XS. Nature 614 521-529 (2023)
  2. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L, Ho DD. Cell 186 279-286.e8 (2023)
  3. Letter ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. Yue C, Song W, Wang L, Jian F, Chen X, Gao F, Shen Z, Wang Y, Wang X, Cao Y. Lancet Infect Dis 23 278-280 (2023)
  4. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Saito A, Tamura T, Zahradnik J, Deguchi S, Tabata K, Anraku Y, Kimura I, Ito J, Yamasoba D, Nasser H, Toyoda M, Nagata K, Uriu K, Kosugi Y, Fujita S, Shofa M, Monira Begum M, Shimizu R, Oda Y, Suzuki R, Ito H, Nao N, Wang L, Tsuda M, Yoshimatsu K, Kuramochi J, Kita S, Sasaki-Tabata K, Fukuhara H, Maenaka K, Yamamoto Y, Nagamoto T, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Ueno T, Schreiber G, Takaori-Kondo A, Genotype to Phenotype Japan (G2P-Japan) Consortium, Shirakawa K, Sawa H, Irie T, Hashiguchi T, Takayama K, Matsuno K, Tanaka S, Ikeda T, Fukuhara T, Sato K. Cell Host Microbe 30 1540-1555.e15 (2022)
  5. Letter Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies. Sheward DJ, Kim C, Fischbach J, Sato K, Muschiol S, Ehling RA, Björkström NK, Karlsson Hedestam GB, Reddy ST, Albert J, Peacock TP, Murrell B. Lancet Infect Dis 22 1538-1540 (2022)
  6. Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. Qu P, Evans JP, Zheng YM, Carlin C, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. Cell Host Microbe 30 1518-1526.e4 (2022)
  7. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains. Starr TN, Greaney AJ, Stewart CM, Walls AC, Hannon WW, Veesler D, Bloom JD. PLoS Pathog 18 e1010951 (2022)
  8. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D, Lozanski G, Panchal A, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. Cell Host Microbe S1931-3128(22)00568-6 (2022)
  9. Letter Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage. Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Sander LE, Kurth F, Klein F. Lancet Infect Dis 22 1422-1423 (2022)
  10. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cao Y, Jian F, Zhang Z, Yisimayi A, Hao X, Bao L, Yuan F, Yu Y, Du S, Wang J, Xiao T, Song W, Zhang Y, Liu P, An R, Wang P, Wang Y, Yang S, Niu X, Zhang Y, Gu Q, Shao F, Hu Y, Yin W, Zheng A, Wang Y, Qin C, Jin R, Xiao J, Xie XS. Cell Rep 41 111845 (2022)
  11. Omicron BA.2.75 Subvariant of SARS-CoV-2 Is Expected to Have the Greatest Infectivity Compared with the Competing BA.2 and BA.5, Due to Most Negative Gibbs Energy of Binding. Popovic M. BioTech (Basel) 11 45 (2022)
  12. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Planas D, Bruel T, Staropoli I, Guivel-Benhassine F, Porrot F, Maes P, Grzelak L, Prot M, Mougari S, Planchais C, Puech J, Saliba M, Sahraoui R, Fémy F, Morel N, Dufloo J, Sanjuán R, Mouquet H, André E, Hocqueloux L, Simon-Loriere E, Veyer D, Prazuck T, Péré H, Schwartz O. Nat Commun 14 824 (2023)
  13. Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia N, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. AIDS 37 709-721 (2023)
  14. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Ito J, Suzuki R, Uriu K, Itakura Y, Zahradnik J, Kimura KT, Deguchi S, Wang L, Lytras S, Tamura T, Kida I, Nasser H, Shofa M, Begum MM, Tsuda M, Oda Y, Suzuki T, Sasaki J, Sasaki-Tabata K, Fujita S, Yoshimatsu K, Ito H, Nao N, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Kuramochi J, Schreiber G, Genotype to Phenotype Japan (G2P-Japan) Consortium, Saito A, Matsuno K, Takayama K, Hashiguchi T, Tanaka S, Fukuhara T, Ikeda T, Sato K. Nat Commun 14 2671 (2023)
  15. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455-456 synergistically enhances antibody evasion and ACE2 binding. Jian F, Feng L, Yang S, Yu Y, Wang L, Song W, Yisimayi A, Chen X, Xu Y, Wang P, Yu L, Wang J, Liu L, Niu X, Wang J, Xiao T, An R, Wang Y, Gu Q, Shao F, Jin R, Shen Z, Wang Y, Wang X, Cao Y. PLoS Pathog 19 e1011868 (2023)
  16. A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein. Thijssen V, Hurdiss DL, Debski-Antoniak OJ, Spence MA, Franck C, Norman A, Aggarwal A, Mokiem NJ, van Dongen DAA, Vermeir SW, Liu M, Li W, Chatziandreou M, Donselaar T, Du W, Drulyte I, Bosch BJ, Snijder J, Turville SG, Payne RJ, Jackson CJ, van Kuppeveld FJM, Jongkees SAK. Proc Natl Acad Sci U S A 120 e2303292120 (2023)
  17. Letter Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies. Chen S, Huang Z, Guo Y, Guo H, Jian L, Xiao J, Yao X, Yu H, Cheng T, Zhang Y, Guan M, Mao R, Zhang J, Xia N, Yuan Q. Cell Discov 9 86 (2023)
  18. Mechanism of a rabbit monoclonal antibody broadly neutralizing SARS-CoV-2 variants. Guo H, Yang Y, Zhao T, Lu Y, Gao Y, Li T, Xiao H, Chu X, Zheng L, Li W, Cheng H, Huang H, Liu Y, Lou Y, Nguyen HC, Wu C, Chen Y, Yang H, Ji X. Commun Biol 6 364 (2023)
  19. SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients-A Single-Center Experience. Totschnig D, Augustin M, Niculescu I, Laferl H, Jansen-Skoupy S, Lehmann C, Wenisch C, Zoufaly A. Viruses 14 2278 (2022)
  20. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, Nasser H, Shofa M, Oda Y, Lytras S, Nao N, Itakura Y, Deguchi S, Suzuki R, Wang L, Begum MM, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Shimizu R, Tsuda M, Kosugi Y, Fujita S, Pan L, Sauter D, Yoshimatsu K, Suzuki S, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Yamamoto Y, Nagamoto T, Schreiber G, Maenaka K, Genotype to Phenotype Japan (G2P-Japan) Consortium, Hashiguchi T, Ikeda T, Fukuhara T, Saito A, Tanaka S, Matsuno K, Takayama K, Sato K. Nat Commun 14 2800 (2023)
  21. Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies. Guo H, Jiang J, Shen S, Ge X, Fan Q, Zhou B, Cheng L, Ju B, Zhang Z. iScience 26 106283 (2023)
  22. An Early and Preliminary Assessment of the Clinical Severity of the Emerging SARS-CoV-2 Omicron Variants in Maharashtra, India. Karyakarte RP, Das R, Taji N, Yanamandra S, Shende S, Joshi S, Karekar B, Bawale R, Tiwari R, Jadhav M, Sakalkar S, Chaudhari G, Rane S, Agarasen J, Pillai P, Dudhate S, Chandankhede P, Labhshetwar R, Gadiyal Y, Rajmane M, Mukade S, Kulkarni P. Cureus 14 e31352 (2022)
  23. An Outbreak of SARS-CoV-2 Omicron Subvariant BA.2.76 in an Outdoor Park - Chongqing Municipality, China, August 2022. Qi L, Tang W, Wang J, Xiong Y, Yuan Y, Li B, Yang L, Li T, Yang L, Su X, Li Q, Zhang L. China CDC Wkly 4 1039-1042 (2022)
  24. An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB. He Q, Wu L, Xu Z, Wang X, Xie Y, Chai Y, Zheng A, Zhou J, Qiao S, Huang M, Shang G, Zhao X, Feng Y, Qi J, Gao GF, Wang Q. Cell Rep Med 4 100991 (2023)
  25. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Liu L, Casner RG, Guo Y, Wang Q, Iketani S, Chan JF, Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L, Ho DD. Immunity 56 2442-2455.e8 (2023)
  26. Antibody escape, the risk of serotype formation, and rapid immune waning: Modeling the implications of SARS-CoV-2 immune evasion. Albright C, Van Egeren D, Thakur A, Chakravarty A, White LF, Stoddard M. PLoS One 18 e0292099 (2023)
  27. BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. Singh J, Anantharaj A, Panwar A, Rani C, Bhardwaj M, Kumar P, Chattopadhyay P, Devi P, Maurya R, Mishra P, Pandey AK, Pandey R, Medigeshi GR. PLoS Pathog 19 e1011196 (2023)
  28. Balancing Functional Tradeoffs between Protein Stability and ACE2 Binding in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB Lineages: Dynamics-Based Network Models Reveal Epistatic Effects Modulating Compensatory Dynamic and Energetic Changes. Verkhivker G, Alshahrani M, Gupta G. Viruses 15 1143 (2023)
  29. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques. Solforosi L, Costes LMM, Tolboom JTBM, McMahan K, Anioke T, Hope D, Murdza T, Sciacca M, Bouffard E, Barrett J, Wu C, Hachmann N, Miller J, Yu J, He X, Jacob-Dolan C, Huber SKR, Dekking L, Chamanza R, Choi Y, Boer KF, Barouch DH, Schuitemaker H, Zahn RC, Wegmann F. Nat Commun 14 1944 (2023)
  30. Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates. Uraki R, Iida S, Halfmann PJ, Yamayoshi S, Hirata Y, Iwatsuki-Horimoto K, Kiso M, Ito M, Furusawa Y, Ueki H, Sakai-Tagawa Y, Kuroda M, Maemura T, Kim T, Mine S, Iwamoto N, Li R, Liu Y, Larson D, Fukushi S, Watanabe S, Maeda K, Wang Z, Ohmagari N, Theiler J, Fischer W, Korber B, Imai M, Suzuki T, Kawaoka Y. Nat Commun 14 1620 (2023)
  31. Clinical and humoral immune response characterization of SARS-CoV-2 Omicron BA.2.38 infection in pediatric patients. Liu Y, Zhao L, Wang L, Li Y, Wang L, Yu B, Hu D, Weng H, Guo J, Yang J, Yang J, Yu X. Heliyon 9 e18093 (2023)
  32. Coarse-Grained Molecular Simulations and Ensemble-Based Mutational Profiling of Protein Stability in the Different Functional Forms of the SARS-CoV-2 Spike Trimers: Balancing Stability and Adaptability in BA.1, BA.2 and BA.2.75 Variants. Verkhivker G, Alshahrani M, Gupta G. Int J Mol Sci 24 6642 (2023)
  33. Comparative Analysis of Conformational Dynamics and Systematic Characterization of Cryptic Pockets in the SARS-CoV-2 Omicron BA.2, BA.2.75 and XBB.1 Spike Complexes with the ACE2 Host Receptor: Confluence of Binding and Structural Plasticity in Mediating Networks of Conserved Allosteric Sites. Alshahrani M, Gupta G, Xiao S, Tao P, Verkhivker G. Viruses 15 2073 (2023)
  34. Comparative Computational Analysis of Spike Protein Structural Stability in SARS-CoV-2 Omicron Subvariants. Balupuri A, Kim JM, Choi KE, No JS, Kim IH, Rhee JE, Kim EJ, Kang NS. Int J Mol Sci 24 16069 (2023)
  35. CovidShiny: An Integrated Web Tool for SARS-CoV-2 Mutation Profiling and Molecular Diagnosis Assay Evaluation In Silico. Ma S, Xiao G, Deng X, Tong M, Huang J, Li Q, Zhang Y. Viruses 15 2017 (2023)
  36. Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection. Lee WS, Tan HX, Reynaldi A, Esterbauer R, Koutsakos M, Nguyen J, Amarasena T, Kent HE, Aggarwal A, Turville SG, Taiaroa G, Kinsella P, Liew KC, Tran T, Williamson DA, Cromer D, Davenport MP, Kent SJ, Juno JA, Khoury DS, Wheatley AK. Sci Adv 9 eadg5301 (2023)
  37. Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies. Wang Y, Gao T, Li W, Tai C, Xie Y, Chen D, Liu S, Huang F, Wang W, Chen Y, Wang B. Cell Biosci 13 160 (2023)
  38. Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76. Singh UB, Deb S, Rani L, Bhardwaj D, Gupta R, Kabra M, Bala K, Kumari L, Perumalla S, Shukla J, Nayer J, Aggarwal P, Ahuja V, Chaudhry R, Sinha S, Guleria R. Lancet Reg Health Southeast Asia 11 100148 (2023)
  39. Humoral and Cellular Immunogenicity of 3 Doses of BNT162b2 in Children With Kidney Diseases. Leung D, Chan EY, Mu X, Rosa Duque JS, Cheng SMS, Ho FT, Tong PC, Lai WM, Lee MHL, Chim S, Tam IYS, Tsang LCH, Kwan KKH, Chung Y, Wong HHW, Lee AMT, Li WY, Sze STK, Lam JHY, Lee DHL, Chan SM, Tu W, Peiris M, Ma AL, Lau YL. Kidney Int Rep 8 2356-2367 (2023)
  40. Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates. Wu Y, Wu N, Jia X, Wu Y, Zhang X, Liu Y, Hou Y, Shen Y, Li E, Wang W, Wang Y, Chiu S. MedComm (2020) 4 e460 (2023)
  41. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies. Bruel T, Stéfic K, Nguyen Y, Toniutti D, Staropoli I, Porrot F, Guivel-Benhassine F, Bolland WH, Planas D, Hadjadj J, Handala L, Planchais C, Prot M, Simon-Lorière E, André E, Baele G, Cuypers L, Mouthon L, Mouquet H, Buchrieser J, Sève A, Prazuck T, Maes P, Terrier B, Hocqueloux L, Schwartz O. Cell Rep Med 3 100850 (2022)
  42. Mechanism of an RBM-targeted rabbit monoclonal antibody 9H1 neutralizing SARS-CoV-2. Chu X, Ding X, Yang Y, Lu Y, Li T, Gao Y, Zheng L, Xiao H, Yang T, Cheng H, Huang H, Liu Y, Lou Y, Wu C, Chen Y, Yang H, Ji X, Guo H. Biochem Biophys Res Commun 660 43-49 (2023)
  43. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants. Roe TL, Brady T, Schuko N, Nguyen A, Beloor J, Guest JD, Aksyuk AA, Tuffy KM, Zhang T, Streicher K, Kelly EJ, Kijak GH. Microbiol Spectr e0033323 (2023)
  44. Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine. Li W, Zhao T, Tao B, Zhao L, Xiao H, Ding X, Li C, Chen L, Cheng H, Lou Y, Chen Y, Wu C. Hum Vaccin Immunother 19 2264589 (2023)
  45. Mutational characterization of Omicron SARS-CoV-2 lineages circulating in Chhattisgarh, a central state of India. Singh P, Sharma K, Shaw D, Bhargava A, Negi SS. Front Med (Lausanne) 9 1082846 (2022)
  46. Omicron BQ.1.1 and XBB.1 unprecedentedly escape broadly neutralizing antibodies elicited by prototype vaccination. Ju B, Fan Q, Liu C, Shen S, Wang M, Guo H, Zhou B, Ge X, Zhang Z. Cell Rep 42 112532 (2023)
  47. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Yisimayi A, Song W, Wang J, Jian F, Yu Y, Chen X, Xu Y, Yang S, Niu X, Xiao T, Wang J, Zhao L, Sun H, An R, Zhang N, Wang Y, Wang P, Yu L, Lv Z, Gu Q, Shao F, Jin R, Shen Z, Xie XS, Wang Y, Cao Y. Nature (2023)
  48. SARS-CoV-2 Omicron Subvariants Balance Host Cell Membrane, Receptor, and Antibody Docking via an Overlapping Target Site. Overduin M, Bhat RK, Kervin TA. Viruses 15 447 (2023)
  49. Meta-Analysis SARS-CoV-2 neutralizing antibody bebtelovimab - a systematic scoping review and meta-analysis. Liew MNY, Kua KP, Lee SWH, Wong KK. Front Immunol 14 1100263 (2023)
  50. Structural basis for broad neutralization of human antibody against Omicron sublineages and evasion by XBB variant. Sun H, Wang Y, Chen X, Jiang Y, Wang S, Huang Y, Liu L, Li Y, Lan M, Guo H, Yuan Q, Zhang Y, Li T, Yu H, Gu Y, Zhang J, Li S, Zheng Z, Zheng Q, Xia N. J Virol 97 e0113723 (2023)
  51. The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era. Boaventura VS, Cerqueira-Silva T, Barral-Netto M. Lancet Infect Dis 23 511-512 (2023)
  52. Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era. Ntanasis-Stathopoulos I, Filippatos C, Gavriatopoulou M, Malandrakis P, Eleutherakis-Papaiakovou E, Spiliopoulou V, Syrigou RE, Theodorakakou F, Fotiou D, Migkou M, Roussou M, Kastritis E, Dimopoulos MA, Terpos E. Diseases 11 123 (2023)


Quick links